Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Other Events

Item8.01.

On June23, 2017, Karyopharm Therapeutics Inc. issued a press
release announcing the presentation of updated interim clinical
data from its Phase 2b SADAL study of selinexor in diffuse large
B-cell lymphoma.

A copy of the press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.

The exhibit to this Current Report on Form 8-K is listed in the
Exhibit Index attached hereto.

Karyopharm Therapeutics Inc. Exhibit
EX-99.1 2 d403215dex991.htm EX-99.1 EX-99.1 Exhibit 99.1      Targeting Disease at the Nuclear Pore Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with “Double- or Triple-Hit” DLBCL With Additional Responders,…
To view the full exhibit click here
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.